Skip to page content

Prescription Drug Benefits

Report

RAND Technical Expert Panel Medicare Advantage (MA) and Part D Contract Star Ratings, February 7, 2022 Meeting

On February 7, 2022, the RAND Corporation convened a Technical Expert Panel web meeting to gather input about the potential development of a measure to capture value-based care arrangements Medicare Advantage organizations have with their contracted providers.

Jun 17, 2022
Journal Article

Access to High-Cost Medications After a Cap on Monthly Out-of-Pocket Spending in California

This cross-sectional study evaluates the association of a cap on monthly out-of-pocket spending on high-cost drugs with use of these drugs and out-of-pocket spending in California in 2015 and 2016.

Mar 4, 2022
Journal Article

Origins of the Opioid Crisis and Its Enduring Impacts

In this paper, we examine the role of the 1996 introduction and marketing of OxyContin as a potential leading cause of the opioid crisis.

Oct 19, 2021
Report

RAND Technical Expert Panel Medicare Advantage (MA) and Part D Contract Star Ratings, May 5, 2021 Meeting

The RAND team gathered input from experts about stratified reporting by Part D low-income subsidy (LIS) and dual eligibility (DE), and disability and assessing social risk factors of Medicare Advantage (MA) and Part D contract beneficiaries.

Aug 5, 2021
Journal Article

Variation in Generic Dispensing Rates in Medicare Part D

Although generic use has increased markedly over time in Part D, substantial variation across plans persists in a number of common therapeutic classes.

Jun 30, 2021
Blog

Biden's First Address to Congress: Insights from RAND

President Joe Biden addressed a joint session of Congress, summarizing his administration's early COVID-19 response and outlining plans that aim to loosen the pandemic's year-long grip on a weary nation. The speech reflected the fact that the United States faces policy challenges across a wide range of domains.

Apr 29, 2021
Journal Article

Psychometric Evaluation of the Medicare Advantage and Prescription Drug Plan Disenrollment Reasons Survey

To develop and assess the reliability and validity of composite measures of reasons for disenrollment from Medicare Advantage and prescription drug plans.

Apr 9, 2021
Report

RAND Technical Expert Panel Medicare Advantage (MA) and Part D Contract Star Ratings, November 12, 2020 Meeting

On November 12, 2020, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input about social risk factors and approaches for ensuring accurate performance measurement.

Mar 16, 2021
Report

RAND Technical Expert Panel Medicare Advantage (MA) and Part D Contract Star Ratings, November 19, 2020 Meeting

On November 19, 2020, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input about stratified reporting of performance and approaches to reduce disparities in Medicare Advantage (MA) and Part D Contracts.

Mar 16, 2021
Report

Balancing Access and Cost Control in the TRICARE Prescription Drug Benefit

The Military Health System provides health and drug coverage to beneficiaries through TRICARE. This report describes the TRICARE pharmacy benefit and the trade-offs in TRICARE pharmacy policies between increasing access and controlling costs.

Jan 14, 2021
Report

RAND Technical Expert Panel Medicare Advantage (MA) and Part D Contract Star Ratings, July 22, 2020 Meeting

On July 22, 2020, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program.

Dec 23, 2020
Commentary

Why States' 'Netflix Model' Prescription Drug Arrangements Are No Silver Bullet

Despite the buzz and catchy notion that subscription models are "Netflix for drugs," it's hard to come up with a theoretical case that supports subscription models over traditional price negotiation between payers and manufacturers over a per-dose or per-unit price.

Jul 1, 2020
Journal Article

How Increasing Medical Access to Opioids Contributes to the Opioid Epidemic: Evidence from Medicare Part D

The national growth in opioid supply explains 75% of the national rise in opioid treatment admissions and the diversion component is a critical driver of the opioid epidemic.

Jun 26, 2020
Report

Subscription Models for Prescription Drugs: The Motivation, Potential, and Limitations of a New Payment Model

The authors argue that, conceptually, the main advantage of subscription models over traditional prescription drug payment arrangements is that they could reduce some sources of uncertainty in spending for payers and in revenue for manufacturers.

May 21, 2020
Journal Article

Association of Medicare Part D Benzodiazepine Coverage Expansion With Changes in Fall-Related Injuries and Overdoses Among Medicare Advantage Beneficiaries

This study found an increase in the rate of overdose after Medicare Part D coverage began to include benzodiazepines among adults aged 65 to 69 years and 80 years or older and an increase in the rate of fall-related injury in adults 80 years or older.

May 5, 2020
Report

RAND Medicare Advantage (MA) and Part D Contract Star Ratings Technical Expert Panel November 7th, 2019 Meeting

On November 7, 2019, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program.

Feb 7, 2020
Commentary

The Promise and Peril of Offshoring Prescription Drug Pricing

Most Americans, including Congress and the president, agree that prescription drug prices are too high. Policy proposals from both major parties could promise some relief. Several of them look to drug prices in other countries to help set prices in the United States.

Sep 16, 2019
Report

RAND Medicare Advantage (MA) and Part D Contract Star Ratings Technical Expert Panel April 30, 2019 Meeting

On April 30, 2019, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program.

Sep 6, 2019
Report

RAND Medicare Advantage (MA) and Part D Contract Star Ratings Technical Expert Panel October 30th 2018 Meeting

On October 30, 2018, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program.

Jan 18, 2019
Multimedia

Albert P. Williams Lecture on Health Policy: What's the Fair Price of a Drug?

In this Events @ RAND podcast, Ezekiel J. Emanuel delivers the 2018 Albert P. Williams Lecture on Health Policy. Emanuel explains why drug prices are so high and proposes a policy solution.

Oct 17, 2018

1
2
3
4
5
6
Next

Research conducted by

RAND Health Care